KALA BIO Statistics
Total Valuation
KALA BIO has a market cap or net worth of $33.91 million. The enterprise value is $24.03 million.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KALA BIO has 6.45 million shares outstanding. The number of shares has increased by 78.73% in one year.
| Current Share Class | 6.45M |
| Shares Outstanding | 6.45M |
| Shares Change (YoY) | +78.73% |
| Shares Change (QoQ) | +35.17% |
| Owned by Insiders (%) | 4.40% |
| Owned by Institutions (%) | 30.13% |
| Float | 3.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.94 |
| P/TBV Ratio | 5.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 5.67.
| Current Ratio | 1.99 |
| Quick Ratio | 1.95 |
| Debt / Equity | 5.67 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.25 |
Financial Efficiency
Return on equity (ROE) is -576.46% and return on invested capital (ROIC) is -60.45%.
| Return on Equity (ROE) | -576.46% |
| Return on Assets (ROA) | -48.51% |
| Return on Invested Capital (ROIC) | -60.45% |
| Return on Capital Employed (ROCE) | -155.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$938,184 |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.29% in the last 52 weeks. The beta is -1.98, so KALA BIO's price volatility has been lower than the market average.
| Beta (5Y) | -1.98 |
| 52-Week Price Change | +12.29% |
| 50-Day Moving Average | 3.84 |
| 200-Day Moving Average | 5.91 |
| Relative Strength Index (RSI) | 68.75 |
| Average Volume (20 Days) | 58,460 |
Short Selling Information
The latest short interest is 294,009, so 4.56% of the outstanding shares have been sold short.
| Short Interest | 294,009 |
| Short Previous Month | 286,860 |
| Short % of Shares Out | 4.56% |
| Short % of Float | 7.81% |
| Short Ratio (days to cover) | 6.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -39.31M |
| Pretax Income | -38.72M |
| Net Income | -35.65M |
| EBITDA | -39.05M |
| EBIT | -39.31M |
| Earnings Per Share (EPS) | -$7.62 |
Full Income StatementBalance Sheet
The company has $42.22 million in cash and $32.35 million in debt, giving a net cash position of $9.87 million or $1.53 per share.
| Cash & Cash Equivalents | 42.22M |
| Total Debt | 32.35M |
| Net Cash | 9.87M |
| Net Cash Per Share | $1.53 |
| Equity (Book Value) | 5.71M |
| Book Value Per Share | 0.88 |
| Working Capital | 22.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.36 million and capital expenditures -$195,000, giving a free cash flow of -$27.56 million.
| Operating Cash Flow | -27.36M |
| Capital Expenditures | -195,000 |
| Free Cash Flow | -27.56M |
| FCF Per Share | -$4.27 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KALA BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -78.73% |
| Shareholder Yield | -78.73% |
| Earnings Yield | -105.14% |
| FCF Yield | -81.27% |
Analyst Forecast
The average price target for KALA BIO is $14.00, which is 166.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.00 |
| Price Target Difference | 166.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 21, 2022. It was a reverse split with a ratio of 0.02:1.
| Last Split Date | Oct 21, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.02:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
